Aceto Propels Growth Strategy with Cascade Chemistry Acquisition
Acquisition strengthens U.S. cGMP custom manufacturing capabilities
PORT WASHINGTON, NY—JUNE 2, 2021— Aceto, a leading global provider of specialty materials for life sciences and advanced technology end markets, announced today the acquisition of Eugene, Oregon-based Cascade Chemistry, manufacturer of active pharmaceutical ingredients (APIs), regulatory starting materials and advanced intermediates. With this acquisition, Aceto now provides customers enhanced support throughout the drug development process and greater access to expanded North American manufacturing, particularly for APIs and advanced intermediates.
Cascade Chemistry is a contract development and manufacturing organization (CDMO) that specializes in tackling challenging synthetic problems for the pharmaceutical and chemical industries, helping clients develop new APIs and move them through the regulatory process into clinical trials. Its track record of creative problem-solving is matched by its strong customer orientation. The company has extensive experience in synthetic route optimization, process development, and scale up of APIs and process intermediates, with differentiated expertise in producing alkaloids, heterocycles, steroids, terpenes, prostaglandins, phenylacetylenes, and chiral syntheses.
“The acquisition of Cascade Chemistry supports and complements our focus on acquisitions that offer customers supply chain choice and technical expertise. With each of our acquisitions, Aceto looks to add companies that enhance our business capabilities and support our growth strategy, while aligning with our core business values,” said Gilles Cottier, Chief Executive Officer of Aceto. “We aim to ensure that all our customers have access to robust solutions that are tailored to their needs and allow them to advance their compounds into clinical trials with confidence and efficiency. Cascade Chemistry is an excellent addition to the Aceto team.”
“Cascade Chemistry has a 40-year track record of applying our deep expertise to solve problems and provide our customers with the support they need to successfully complete the challenging and complex API development cycle,” said Jeremiah Marsden, President of Cascade Chemistry. “We are proud of our reputation for quality and outstanding customer service and we welcome the opportunity to now join forces with Aceto. Access to the expanded capabilities of the Aceto family of companies will allow us to serve our clients with comprehensive, fully integrated support teams and additional service options that will further enhance and accelerate our clients’ programs.”
Cascade Chemistry recently announced construction of new state-of-the-art facilities which will triple manufacturing capacity for APIs for clinical trials and ultimately commercial production. The new facility is expected to be operational in 2022 and will significantly add to the combined entity’s GMP capacity and scale.
Wombat Capital Markets, LLC acted as financial advisor to Cascade Chemistry. Financial terms were not disclosed. For more information, please visit Aceto.com.